- Home
- BCG vs MAIA Comparison
BCG vs MAIA Comparison
Compare BCG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- MAIA
- Stock Information
- Founded
- BCG 2016
- MAIA 2018
- Country
- BCG United States
- MAIA United States
- Employees
- BCG N/A
- MAIA N/A
- Industry
- BCG
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- MAIA Health Care
- Exchange
- BCG Nasdaq
- MAIA Nasdaq
- Market Cap
- BCG 42.3M
- MAIA 46.7M
- IPO Year
- BCG N/A
- MAIA 2022
- Fundamental
- Price
- BCG $2.27
- MAIA $2.01
- Analyst Decision
- BCG
- MAIA
- Analyst Count
- BCG 0
- MAIA 0
- Target Price
- BCG N/A
- MAIA N/A
- AVG Volume (30 Days)
- BCG 48.5K
- MAIA 141.8K
- Earning Date
- BCG 05-26-2025
- MAIA 05-13-2025
- Dividend Yield
- BCG N/A
- MAIA N/A
- EPS Growth
- BCG N/A
- MAIA N/A
- EPS
- BCG N/A
- MAIA N/A
- Revenue
- BCG $164,877,000.00
- MAIA N/A
- Revenue This Year
- BCG N/A
- MAIA N/A
- Revenue Next Year
- BCG N/A
- MAIA N/A
- P/E Ratio
- BCG N/A
- MAIA N/A
- Revenue Growth
- BCG 1.25
- MAIA N/A
- 52 Week Low
- BCG $1.71
- MAIA $1.40
- 52 Week High
- BCG $12.22
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- MAIA 70.78
- Support Level
- BCG N/A
- MAIA $1.51
- Resistance Level
- BCG N/A
- MAIA $1.61
- Average True Range (ATR)
- BCG 0.00
- MAIA 0.14
- MACD
- BCG 0.00
- MAIA 0.06
- Stochastic Oscillator
- BCG 0.00
- MAIA 71.91
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.